136 related articles for article (PubMed ID: 9093726)
1. High-versus low-dose levo-leucovorin as a modulator of 5-fluorouracil in advanced colorectal cancer: a 'GISCAD' phase III study. Italian Group for the Study of Digestive Tract Cancer.
Labianca R; Cascinu S; Frontini L; Barni S; Fiorentini G; Comella G; Zaniboni A; Gottardi O; Arnoldi E; Oliani C; Duro M; Pavanato G; Martignoni G; Raina A; Piazza E; Dallavalle G; Valsecchi R; Pancera G; Luporini G
Ann Oncol; 1997 Feb; 8(2):169-74. PubMed ID: 9093726
[TBL] [Abstract][Full Text] [Related]
2. Activity of high dose 24 hour 5-fluorouracil infusion plus L-leucovorin in advanced colorectal cancer.
Nobile MT; Barzacch MC; Sanguineti O; Chiara S; Gozza A; Vincenti M; Lavarello A; Cognein P; Lionetto R; Percivale PL; Bertoglio S; Murolo C; Esposito M; Vannozzi MO; Rosso R
Anticancer Res; 1998; 18(1B):517-21. PubMed ID: 9568171
[TBL] [Abstract][Full Text] [Related]
3. Folinic acid + 5-fluorouracil (5-FU) versus equidose 5-FU in advanced colorectal cancer. Phase III study of 'GISCAD' (Italian Group for the Study of Digestive Tract Cancer).
Labianca R; Pancera G; Aitini E; Barni S; Beretta A; Beretta GD; Cesana B; Comella G; Cozzaglio L; Cristoni M
Ann Oncol; 1991 Oct; 2(9):673-9. PubMed ID: 1742223
[TBL] [Abstract][Full Text] [Related]
4. 5-Fluorouracil combined with the [6S]-stereoisomer of folinic acid in high doses for treatment of patients with advanced colorectal carcinoma. A phase I-II study of two consecutive regimens.
Machover D; Grison X; Goldschmidt E; Zittoun J; Metzger G; Richaud J; Lotz JP; André T; Hannoun L; Marquet J
Ann Oncol; 1993; 4 Suppl 2():29-35. PubMed ID: 8353102
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952.
Köhne CH; Wils J; Lorenz M; Schöffski P; Voigtmann R; Bokemeyer C; Lutz M; Kleeberg C; Ridwelski K; Souchon R; El-Serafi M; Weiss U; Burkhard O; Rückle H; Lichnitser M; Langenbuch T; Scheithauer W; Baron B; Couvreur ML; Schmoll HJ;
J Clin Oncol; 2003 Oct; 21(20):3721-8. PubMed ID: 12963704
[TBL] [Abstract][Full Text] [Related]
6. Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. Corfu-A Study Group.
J Clin Oncol; 1995 Apr; 13(4):921-8. PubMed ID: 7707120
[TBL] [Abstract][Full Text] [Related]
7. Fluorouracil combined with the pure (6S)-stereoisomer of folinic acid in high doses for treatment of patients with advanced colorectal carcinoma: a phase I-II study.
Machover D; Grison X; Goldschmidt E; Zittoun J; Lotz JP; Metzger G; Richaud J; Hannoun L; Marquet J; Guillot T
J Natl Cancer Inst; 1992 Mar; 84(5):321-7. PubMed ID: 1738182
[TBL] [Abstract][Full Text] [Related]
8. Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase II-III randomized trial.
Comella P; De Vita F; Mancarella S; De Lucia L; Biglietto M; Casaretti R; Farris A; Ianniello GP; Lorusso V; Avallone A; Cartenì G; Leo SS; Catalano G; De Lena M; Comella G
Ann Oncol; 2000 Oct; 11(10):1323-33. PubMed ID: 11106123
[TBL] [Abstract][Full Text] [Related]
9. Sequential methotrexate, 5-fluorouracil (5-FU), and high dose leucovorin versus 5-FU and high dose leucovorin versus 5-FU alone for advanced colorectal cancer. A multi-institutional randomized trial.
Abad A; Garcia P; Gravalos C; Tusquets I; Font A; Perez G; Cortés-Funes H; Fabregat X; Barnadas A; Rosell R
Cancer; 1995 Mar; 75(6):1238-44. PubMed ID: 7882275
[TBL] [Abstract][Full Text] [Related]
10. Schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a randomized study. GISCAD, IOR and collaborating centers.
Sobrero A; Zaniboni A; Frassineti GL; Aschele C; Guglielmi A; Giuliani R; Ravaioli A; Lanfranco C; Caroti C; Arnoldi E; Barni S; Gallo L; Pessi MA; Turci D; Cortesi E; Grossi F; Frontini L; Piazza E; Bruzzi P; Labianca R
Ann Oncol; 2000 Nov; 11(11):1413-20. PubMed ID: 11142481
[TBL] [Abstract][Full Text] [Related]
11. Outpatient weekly high-dose continuous-infusion 5-fluorouracil plus oral leucovorin in advanced colorectal cancer. A phase II trial. Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD).
Aranda E; Cervantes A; Carrato A; Fernández-Martos C; Antón-Torres A; Massutí T; Barneto I; García-Conde J; Barón JM; Díaz-Rubio E
Ann Oncol; 1996 Aug; 7(6):581-5. PubMed ID: 8879371
[TBL] [Abstract][Full Text] [Related]
12. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.
de Gramont A; Bosset JF; Milan C; Rougier P; Bouché O; Etienne PL; Morvan F; Louvet C; Guillot T; François E; Bedenne L
J Clin Oncol; 1997 Feb; 15(2):808-15. PubMed ID: 9053508
[TBL] [Abstract][Full Text] [Related]
13. Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer.
Schilsky RL; Levin J; West WH; Wong A; Colwell B; Thirlwell MP; Ansari RH; Bell WN; White RL; Yates BB; McGuirt PV; Pazdur R
J Clin Oncol; 2002 Mar; 20(6):1519-26. PubMed ID: 11896100
[TBL] [Abstract][Full Text] [Related]
14. Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure l-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III study.
Scheithauer W; Kornek G; Marczell A; Salem G; Karner J; Kovats E; Burger D; Greiner R; Pidlich J; Schneeweiss B; Raderer M; Rosen H; Depisch D
J Clin Oncol; 1997 Mar; 15(3):908-14. PubMed ID: 9060527
[TBL] [Abstract][Full Text] [Related]
15. Advanced colorectal carcinoma. A prospective randomized trial of sequential methotrexate, 5-fluorouracil, and leucovorin versus 5-fluorouracil alone.
Machiavelli M; Leone BA; Romero A; Rabinovich MG; Vallejo CT; Bianco A; Pérez JE; Rodríguez R; Cuevas MA; Alvarez LA
Am J Clin Oncol; 1991 Jun; 14(3):211-7. PubMed ID: 2031508
[TBL] [Abstract][Full Text] [Related]
16. Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1.
Jäger E; Heike M; Bernhard H; Klein O; Bernhard G; Lautz D; Michaelis J; Meyer zum Büschenfelde KH; Knuth A
J Clin Oncol; 1996 Aug; 14(8):2274-9. PubMed ID: 8708717
[TBL] [Abstract][Full Text] [Related]
17. Concurrent irinotecan and 5-fluorouracil plus levo-folinic acid given every other week in the first-line management of advanced colorectal carcinoma: a phase I study of the Southern Italy Cooperative Oncology Group.
Comella P; Casaretti R; De Vita F; Avallone A; Orditura M; Petrillo A; Gravina A; Faranda A; Comis S; Comella G; Catalano G
Ann Oncol; 1999 Aug; 10(8):915-21. PubMed ID: 10509152
[TBL] [Abstract][Full Text] [Related]
18. [Chronotherapy with high dose carboplatin, 5-fluorouracil and leucovorin in advanced colorectal carcinoma].
Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević A
Srp Arh Celok Lek; 1998; 126(9-10):355-61. PubMed ID: 9863407
[TBL] [Abstract][Full Text] [Related]
19. Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: a randomized trial of the Northern California Oncology Group.
Valone FH; Friedman MA; Wittlinger PS; Drakes T; Eisenberg PD; Malec M; Hannigan JF; Brown BW
J Clin Oncol; 1989 Oct; 7(10):1427-36. PubMed ID: 2789272
[TBL] [Abstract][Full Text] [Related]
20. The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: results of a phase III trial. Swiss Group for Clinical Cancer Research (SAKK).
Borner MM; Castiglione M; Bacchi M; Weber W; Herrmann R; Fey MF; Pagani O; Leyvraz S; Morant R; Pestalozzi B; Hanselmann S; Goldhirsch A
Ann Oncol; 1998 May; 9(5):535-41. PubMed ID: 9653495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
